UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

05 UCB’s HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment

Read More Share:

Jul

08 UCB extends its BIMZELX® “Get Yourself Back” direct-to-consumer campaign for the hidradenitis suppurativa community

Read More Share:

Jun

17 Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.

Read More Share:

Jun

12 UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Read More Share:

Jun

11 BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:

Apr

03 UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

Read More Share:

Mar

19 New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

Read More Share:

Mar

12 Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

Read More Share:

Mar

07 BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Read More Share:

Mar

07 BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Read More Share:

Categories

Archives

Aug

05

UCB’s HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment

Jul

08

UCB extends its BIMZELX® “Get Yourself Back” direct-to-consumer campaign for the hidradenitis suppurativa community

Jun

17

Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.

Jun

12

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Jun

11

BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis

Apr

03

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

Mar

19

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

Mar

12

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

Mar

07

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Mar

07

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Aug

05

UCB’s HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment

Jul

08

UCB extends its BIMZELX® “Get Yourself Back” direct-to-consumer campaign for the hidradenitis suppurativa community

Jun

17

Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.

Jun

12

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Jun

11

BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis

Apr

03

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

Mar

19

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

Mar

12

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

Mar

07

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Mar

07

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact